Warfarin and Acitrom Titration
Starting and adjusting warfarin or acitrom to target, and converting between them · v1.9- Enter the current INR, the weekly dose and the target range.
- Work in the total weekly dose, never a daily average: 3 mg on three days and 2 mg on the other four is 17 mg a week.
- Select the indication and the target INR and the bridging decision follow from it.
- You get the total weekly dose adjustment, day-by-day initiation nomograms, and conversion between the two vitamin K antagonists.
- Direct oral anticoagulants, and the choice between one of them and a vitamin K antagonist.
- The indication and the target INR, both of which the page assumes were settled before it was opened.
- Stopping and restarting the drug around surgery or a procedure.
- The dose of the parenteral anticoagulant where bridging is indicated. It says whether to bridge and for how long, and names no heparin figure.
1. Clinical Objective & Agent
2. Clinical Parameters
Practice Pearl: Always calculate based on the Total Weekly Dose (TWD). Do not use daily averages. E.g., 3mg Mon/Wed/Fri + 2mg other days = TWD of 17mg.
Evidence & Clinical Pearls
1. Pathophysiology: The Procoagulant Window
VKAs (Warfarin, Acenocoumarol) inhibit Vitamin K Epoxide Reductase, which prevents the activation of clotting factors II, VII, IX, and X. They deplete Protein C and Protein S at the same time, and those two natural anticoagulants have much shorter half-lives than Factor II. The body's own brakes therefore come off within hours while Factor II takes days to fall, and the patient is transiently hypercoagulable through the first 3-5 days of therapy. That is the reasoning behind bridging with LMWH or unfractionated heparin until the INR reflects true Factor II depletion.
- It does not follow that every patient needs it. ACCP 2012 bridges where the risk being covered is acute: venous thromboembolism under treatment, and a mechanical valve.
- It does not bridge atrial fibrillation or a bioprosthetic valve, where the daily thrombotic risk is low and the bleeding cost of a parenteral anticoagulant is not repaid.
2. Warfarin and Acenocoumarol Compared
| Pharmacokinetic Feature | Warfarin | Acenocoumarol (Acitrom) |
|---|---|---|
| Half-Life (T½) | Long (36 - 42 hours) | Short (8 - 11 hours) |
| Time to Steady State | 5 to 7 days | 2 to 3 days |
| Clinical Implication | More stable INRs; missing a single dose causes minor fluctuations. | Faster onset/offset. Missing a single dose causes a rapid drop in INR, increasing immediate stroke/clot risk. |
| Equivalent Dose Ratio | 5 mg | 2 mg (Acitrom is ~2.5x more potent per mg) |
3. Indian Clinical Context: Substitution Caution
Switching between generics needs an INR check. In Indian OPDs and government hospitals, patients frequently substitute brands on pharmacy availability, switching from Warf to Uniwarf for example. Generic naming confusion can also put a patient on Acitrom when the prescription said Warfarin, which is a different drug at a different potency. Different brands have varying bioavailability. Always mandate an INR check 5 to 7 days after any brand or formulation change.
4. Target INR: 2.5 for Almost Everything, 3.0 for a Mechanical Mitral Valve
- 2.5 (Range 2.0 - 3.0) for almost all standard indications, including DVT/PE, AFib and Bioprosthetic valves.
- 3.0 (Range 2.5 - 3.5) for the Mechanical Mitral Valve, because of the high-flow, high-thrombogenicity environment of the mitral position.
- 2.5 in ACCP 2012 for a bileaflet mechanical valve in the aortic position in a patient with no additional risk factor. This tool takes the mechanical valve option at 3.0, so confirm the target against the operation note.
5. Important Drug Interactions
| Increase INR (Bleeding Risk) | Decrease INR (Clotting Risk) |
|---|---|
| Amiodarone (Reduces VKA dose requirement by ~30-50%) | Rifampicin, and therefore any rifampicin-containing antitubercular regimen |
| Macrolides, Fluoroquinolones | Carbamazepine, Phenytoin |
| Azole antifungals, Metronidazole | Phenobarbital |
| Cotrimoxazole (a large rise; both CYP2C9 inhibition and displacement) | Cholestyramine |
| NSAIDs (Increase bleeding risk independent of INR) | Griseofulvin |
6. Antitubercular Therapy and the VKA Dose
This is the interaction that comes up most often on an Indian ward, and the source guidelines barely mention it. Rifampicin is a potent inducer of CYP2C9, CYP3A4 and P-glycoprotein, and a patient started on a rifampicin-containing regimen under the National Tuberculosis Elimination Programme will need a substantially larger weekly dose of warfarin or acenocoumarol to hold the same INR. Induction takes about a week to build and does not wear off for two to three weeks after rifampicin stops.
- Check the INR 5 to 7 days after antitubercular therapy starts, then weekly until it settles.
- Titrate on this page in the usual way. Do not make one large jump.
- Repeat the same sequence when rifampicin is stopped. The dose that was right on treatment will be too much once induction fades, and that is when the INR climbs.
- Never adjust the antitubercular regimen to suit the anticoagulant. Where the two cannot be reconciled, the question is whether this patient should be on a vitamin K antagonist at all.
Abbreviations
AF (Atrial Fibrillation) · AFib (Atrial Fibrillation) · CYP2C9 (Cytochrome P450 2C9) · DVT (Deep Vein Thrombosis) · INR (International Normalised Ratio) · LMWH (Low Molecular Weight Heparin) · NSAID (Non-Steroidal Anti-Inflammatory Drug) · OPD (Outpatient Department) · PE (Pulmonary Embolism) · TWD (Total Weekly Dose) · VKA (Vitamin K Antagonist) · VTE (Venous Thromboembolism)References
- Stevens SM, Woller SC, Kreuziger LB, et al. Antithrombotic Therapy for VTE Disease: Second Update of the CHEST Guideline and Expert Panel Report. Chest. 2021;160(6):e545-e608.
- Douketis JD, Spyropoulos AC, Murad MH, et al. Perioperative Management of Antithrombotic Therapy: An American College of Chest Physicians Clinical Practice Guideline. Chest. 2022;162(5):e207-e243.
- Holbrook A, et al. Evidence-Based Management of Anticoagulant Therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012. [Superseded; source of the INR targets and titration nomogram used here]
- Tait RC, Sellar L. A novel rapid-induction regimen for warfarin. Br J Haematol. 1998.
- Indian College of Cardiology / Association of Physicians of India (API). National Consensus on Management of Venous Thromboembolism. J Assoc Physicians India. 2018.
How to Cite This Tool
DOIhttps://doi.org/10.5281/zenodo.22401661
AMA Style:Umakanth S. Warfarin and Acitrom Titration. Version 1.9. MEDiscuss Clinical Decision Support System. Published 2026. Accessed . https://mediscuss.org/cdss/vka-titration. doi:10.5281/zenodo.22401661
Vancouver Style:Umakanth S. Warfarin and Acitrom Titration [Internet]. Version 1.9. MEDiscuss.org; 2026 [cited ]. Available from: https://mediscuss.org/cdss/vka-titration. doi:10.5281/zenodo.22401661
Save this calculation
Whatever you type here stays on this device and is not sent anywhere. The server receives only a scrambled code made from it, so nobody with access to the server can tell which patient a saved calculation belongs to. Enter the same nickname the next time to see that patient's earlier values. What is stored
Category Therapeutic & Management PathwaysPathway
Specialties Internal Medicine, Cardiology